Spotlight Top Pick InVitae Corp (NYSE:NVTA) has seen its stock decline and one culprit was a recently published article “How a cancer test maker started by former Twitter, Google execs hopes to change ...

They don’t have any preferred status over Invitae at any network. In the end, as with much other new in the area, we are encouraged in interest and any additional visibility that is brought to bear on ...

SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be ...

BURLINGTON, N.C. - Labcorp (NYSE: LH), a prominent provider of laboratory services, announced today the acquisition of select assets from Invitae (OTC:NVTAQ), a medical genetics company. This ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...

SYDNEY, AUSTRALIA / ACCESSWIRE / March 13, 2018 / Medical clinic and research facility Olympus Genetics Pty Ltd, based in Sydney Olympic Park, NSW, Australia, are pleased to announce the provision of ...

Millions of people globally struggle with rare diseases, often facing limited treatment options due to fragmented care and a lack of research resources. In many cases, the diagnostic odyssey - moving ...